Many drugs that are available in the overseas market have not yet been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan. A study of the top 100 drugs by sales in 2004 shows a 2.5-year gap between the launch dates in the UK/US and Japan [1] . Of a total of 398 new chemical entities that were approved in either the US, EU, or Japan between 1999 and 2007, 325 (82%) were approved in the US, 314 (79%) in the EU, but only 220 (55%) were approved in Japan [2] . This gap, or so-called drug lag, differs among drugs with different therapeutic indications. Drugs against infectious diseases have short lags, whereas those for the treatment of the central nervous system diseases have much longer lags [2, 3] . The lag prevents Japanese patients with neurological diseases from accessing these drugs at the same time as patients in other developed nations access them. Further, it may even delay the progress of clinical research in Japan.
We analysed Japanese and UK data regarding the approval of new neurological [4] , the regulation of drugs is harmonised between Japan and the UK; in addition, the UK, like Japan, provides a national health service that covers the neurological drugs discussed in the present study.
We defined approval lag as the difference between the date of approval in Japan and the date of first authorization in the UK. Japan's review time was defined as the time between the date of application for approval and the date of approval.
During the 11 years from June 1999 and April 2010, 22 new neurological drugs were introduced in Japan (Table) . Of these, 20 were already available in the UK when they were approved in Japan, with a median lag of 65 months. The median review time (from application for approval to approval) of these 20 drugs was 22 months. Only clobazam and sumatriptan succinate were first approved in Japan and then in the UK, with lag times of 22 months and 20 months, respectively. Sixteen neurological drugs were available in the UK but not in Japan.
Few studies have quantified Japan's drug lag in terms of therapeutic indications. Hirai et al. [3] studied a data set of all new molecular entities and new biologics approved between January 2000 and December 2006 in Japan, the US, and the EU and showed that Japan's median delay in development time was 35.5 months.
Among drugs from different therapeutic areas, those for central nervous system diseases showed the longest delay of 53.5 months [3] . Our analysis, focusing on the introduction of new neurological drugs, showed that Japan lags behind the UK by 65 months.
Drug lag consists of the delay in development time (i.e. up to application for approval) as well as review time. The median review time of 22 months observed in our study was longer than the European Medicines Agency (EMA) review time of 13.5 months [5] . However, this 9-month difference cannot explain the overall lag of 65 months. Although we could not precisely identify the development time, the above data show that most of the lag is presumably due to delays in development, not review. In contrast to these 22 drugs already approved in Japan, 16 (42%) of 38 drugs are approved in the UK but not in Japan, showing the so-called absolute drug lag [2] .
The data presented in this study confirm that Japan's drug lag in the case of neurological drugs is quite substantial and keeps Japanese patients from the benefits of new treatments. The general public in Japan hopes that the simultaneous development of drugs on a global scale and improvements of the regulatory system would effectively reduce the delay, but the following problems make this goal seem difficult to achieve. First, the difference in the prevalence of some neurological disorders, e.g., multiple sclerosis, between Japan and the UK makes it difficult to recruit sufficient numbers of patients for clinical trials in Japan. Second, language problems among Japanese participants in multinational trials delay the development of new drugs in Japan. Third, the high cost and underperformance of clinical trials in Japan [2, 3] may have a significant effect on drug lag.
Our results underscore the necessity for further analysis into the causes of the lag, with close attention not only to the role played by the Japanese regulatory authority but also to that played by the pharmaceutical companies and citizens.
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